INS and obesity due to melanocortin 4 receptor deficiency: Although contraindicated during pregnancy, these anti-obesity drugs simultaneously improve insulin sensitivity, reduce cardiovascular disease risk, and show promising potential in achieving and maintaining weight loss [46].